Juno Therapeutics Inc (NASDAQ:JUNO) reported financial results and business highlights for the fourth quarter and year ended December 31, 2016. “2016 was a …
Alcobra Ltd Alcobra Ltd (NASDAQ:ADHD) lost half of its value today after announcing that the top-line results from MEASURE, the company’s second Phase …
J.P.
Juno Therapeutics Inc (NASDAQ:JUNO) and Celgene Corporation (NASDAQ:CELG) announced that the U.S.
Juno Therapeutics Inc (NASDAQ:JUNO) announced that it has defeated an attempt to invalidate a patent exclusively licensed by Juno that covers, among other …
Juno Therapeutics Inc (NASDAQ:JUNO) provided an update of key data from studies of its investigational chimeric antigen receptor (CAR) T cell product candidates, …
Maxim analyst Jason McCarthy provides insight on Juno Therapeutics Inc (NASDAQ:JUNO) amid the hold placed on the firm’s JCAR015 ROCKET study, which arose …
Juno Therapeutics Inc (NASDAQ:JUNO) announced encouraging preliminary clinical data for JCAR017 in patients with relapsed or refractory (r/r) aggressive non-Hodgkin lymphoma (NHL) in …
Juno Therapeutics Inc (NASDAQ:JUNO) shares are falling 4% after last week’s hit: the firm’s pivotal ROCKET trial of JCAR015, a product candidate in …
Shares of Juno Therapeutics Inc (NASDAQ:JUNO) fall as Wall Street continues to debate the unexpected patient deaths and clinical hold for the company’s Phase …
